Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 25

1.

Effects of Chemotherapy in Patients with Concomitant Aortic Aneurysm and Malignant Disease.

Leopardi M, Di Marco E, Musilli A, Ricevuto E, Bruera G, Ventura M.

Ann Vasc Surg. 2017 Jul 21. pii: S0890-5096(17)30908-1. doi: 10.1016/j.avsg.2017.07.013. [Epub ahead of print]

PMID:
28739458
2.

Clinical parameters to guide decision-making in elderly metastatic colorectal CANCER patients treated with intensive cytotoxic and anti-angiogenic therapy.

Bruera G, Russo A, Galvano A, Rizzo S, Ricevuto E.

Oncotarget. 2017 Jun 6;8(23):37875-37883. doi: 10.18632/oncotarget.14333.

3.

Ticagrelor versus Aspirin in Acute Stroke or Transient Ischemic Attack.

Johnston SC, Amarenco P, Albers GW, Denison H, Easton JD, Evans SR, Held P, Jonasson J, Minematsu K, Molina CA, Wang Y, Wong KS; SOCRATES Steering Committee and Investigators.

N Engl J Med. 2016 Jul 7;375(1):35-43. doi: 10.1056/NEJMoa1603060. Epub 2016 May 10.

4.

Dose-dense nonpegylated liposomal Doxorubicin and docetaxel combination in breast cancer: dose-finding study.

Ricevuto E, Cocciolone V, Mancini M, Cannita K, Romano S, Bruera G, Pelliccione M, Adinolfi MI, Ciccozzi A, Bafile A, Penco M, Ficorella C.

Oncologist. 2015 Feb;20(2):109-10. doi: 10.1634/theoncologist.2014-0129. Epub 2015 Jan 19.

5.

The prevalent KRAS exon 2 c.35 G>A mutation in metastatic colorectal cancer patients: A biomarker of worse prognosis and potential benefit of bevacizumab-containing intensive regimens?

Bruera G, Cannita K, Tessitore A, Russo A, Alesse E, Ficorella C, Ricevuto E.

Crit Rev Oncol Hematol. 2015 Mar;93(3):190-202. doi: 10.1016/j.critrevonc.2014.10.004. Epub 2014 Oct 16. Review.

PMID:
25459669
6.

Bioclinical parameters driving decision-making of subsequent lines of treatment in metastatic castration-resistant prostate cancer.

Irelli A, Bruera G, Cannita K, Palluzzi E, Gravina GL, Festuccia C, Ficorella C, Ricevuto E.

Biomed Res Int. 2014;2014:909623. doi: 10.1155/2014/909623. Epub 2014 May 28. Review.

7.

Multidisciplinary management of hepatocellular carcinoma in clinical practice.

Bruera G, Cannita K, Giordano AV, Manetta R, Vicentini R, Carducci S, Saltarelli P, Iapadre N, Coletti G, Ficorella C, Ricevuto E.

Biomed Res Int. 2014;2014:806391. doi: 10.1155/2014/806391. Epub 2014 May 8.

8.

Prognostic relevance of KRAS genotype in metastatic colorectal cancer patients unfit for FIr-B/FOx intensive regimen.

Bruera G, Cannita K, Giordano AV, Vicentini R, Ficorella C, Ricevuto E.

Int J Oncol. 2014 Jun;44(6):1820-30. doi: 10.3892/ijo.2014.2369. Epub 2014 Apr 4.

9.

Effectiveness and safety of intensive triplet chemotherapy plus bevacizumab, FIr-B/FOx, in young-elderly metastatic colorectal cancer patients.

Bruera G, Cannita K, Giordano AV, Vicentini R, Ficorella C, Ricevuto E.

Biomed Res Int. 2013;2013:143273. doi: 10.1155/2013/143273. Epub 2013 Nov 6.

10.

Differential prognosis of metastatic colorectal cancer patients post-progression to first-line triplet chemotherapy plus bevacizumab, FIr-B/FOx, according to second-line treatment and KRAS genotype.

Bruera G, Cannita K, Giordano AV, Vicentini R, Ficorella C, Ricevuto E.

Int J Oncol. 2014 Jan;44(1):17-26. doi: 10.3892/ijo.2013.2179. Epub 2013 Nov 15.

11.

Close correlation between MEK/ERK and Aurora-B signaling pathways in sustaining tumorigenic potential and radioresistance of gynecological cancer cell lines.

Marampon F, Gravina GL, Popov VM, Scarsella L, Festuccia C, La Verghetta ME, Parente S, Cerasani M, Bruera G, Ficorella C, Ricevuto E, Tombolini V, Di Cesare E, Zani BM.

Int J Oncol. 2014 Jan;44(1):285-94. doi: 10.3892/ijo.2013.2167. Epub 2013 Nov 5.

PMID:
24189697
12.

Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial.

SPS3 Study Group, Benavente OR, Coffey CS, Conwit R, Hart RG, McClure LA, Pearce LA, Pergola PE, Szychowski JM.

Lancet. 2013 Aug 10;382(9891):507-15. doi: 10.1016/S0140-6736(13)60852-1. Epub 2013 May 29. Erratum in: Lancet. 2013 Aug 10;382(9891):506. Coffey, C S [aded].

13.

Worse prognosis of KRAS c.35 G > A mutant metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx).

Bruera G, Cannita K, Di Giacomo D, Lamy A, Fr├ębourg T, Sabourin JC, Tosi M, Alesse E, Ficorella C, Ricevuto E.

BMC Med. 2013 Mar 4;11:59. doi: 10.1186/1741-7015-11-59.

14.

Prognostic value of KRAS genotype in metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx) according to extension of metastatic disease.

Bruera G, Cannita K, Di Giacomo D, Lamy A, Troncone G, Dal Mas A, Coletti G, Fr├ębourg T, Sabourin JC, Tosi M, Ficorella C, Ricevuto E.

BMC Med. 2012 Nov 8;10:135. doi: 10.1186/1741-7015-10-135.

15.

Effects of clopidogrel added to aspirin in patients with recent lacunar stroke.

SPS3 Investigators, Benavente OR, Hart RG, McClure LA, Szychowski JM, Coffey CS, Pearce LA.

N Engl J Med. 2012 Aug 30;367(9):817-25. doi: 10.1056/NEJMoa1204133.

16.

Triplet chemotherapy in patients with metastatic colorectal cancer: toward the best way to safely administer a highly active regimen in clinical practice.

Ficorella C, Bruera G, Cannita K, Porzio G, Baldi PL, Tinari N, Natoli C, Ricevuto E.

Clin Colorectal Cancer. 2012 Dec;11(4):229-37. doi: 10.1016/j.clcc.2012.05.001. Epub 2012 Jun 12. Review.

PMID:
22694897
17.

Effectiveness of liver metastasectomies in patients with metastatic colorectal cancer treated with FIr-B/FOx triplet chemotherapy plus bevacizumab.

Bruera G, Cannita K, Giuliante F, Lanfiuti Baldi P, Vicentini R, Marchetti P, Nuzzo G, Antonucci A, Ficorella C, Ricevuto E.

Clin Colorectal Cancer. 2012 Jun;11(2):119-26. doi: 10.1016/j.clcc.2011.11.002. Epub 2011 Dec 27.

PMID:
22206922
18.

Modulation of GemOx chemotherapy according to CIRS in elderly patients with advanced pancreatic cancer.

Tudini M, Palluzzi E, Cannita K, Mancini M, Santomaggio A, Bruera G, Baldi PL, Pelliccione M, Ricevuto E, Ficorella C.

Oncol Rep. 2012 Feb;27(2):423-32. doi: 10.3892/or.2011.1517. Epub 2011 Oct 21.

PMID:
22020810
20.

"Poker" association of weekly alternating 5-fluorouracil, irinotecan, bevacizumab and oxaliplatin (FIr-B/FOx) in first line treatment of metastatic colorectal cancer: a phase II study.

Bruera G, Santomaggio A, Cannita K, Baldi PL, Tudini M, De Galitiis F, Mancini M, Marchetti P, Antonucci A, Ficorella C, Ricevuto E.

BMC Cancer. 2010 Oct 19;10:567. doi: 10.1186/1471-2407-10-567.

Supplemental Content

Loading ...
Support Center